Pharmacological Effects of Novel Peptide Drugs on Allergic Rhinitis at the Small Ribonucleic Acids Level

Abstract

Using an allergic rhinitis (AR) model, we evaluated the pharmacological effects of novel peptide drugs (P-ONE and P-TWO) at the small RNA (sRNA) level. Using highthroughput sequencing, we assessed the sRNA expression profile of the negative control, AR antagonist (positive control), P-ONE, and P-TWO groups. By functional clustering and Gene Ontology and KEGG pathway analyses, we found that sRNA target genes have a specific enrichment pattern and may contribute to the effects of the novel peptides. Small RNA sequencing confirmed the biological foundations of novel and traditional AR treatments and suggested unique pharmacological effects. Our findings will facilitate evaluation of the pathogenesis of AR and of the pharmacological mechanisms of novel peptide drugs.

Study on the Mechanism of Allergic Rhinitis Based on the Expression of FIB, PCT, hs-CRP, and Th17/Treg-IL10/IL-17 Axis Balance

“…Allergic rhinitis (AR) is a non-infectious inflammatory disease of nasal mucosa mediated by immunoglobulin E (IgE) and affected by various inflammatory factors. 1 AR is mostly caused by antibody sensitization produced in the immune system. After the allergen enters the body, the mediator cells in the body are stimulated to release active substances, resulting in increased capillary permeability and cholinergic reaction, as well as persistent sneezing, runny nose, nasal itching, nasal congestion, and other symptoms.…”